Back to today’s briefing

Story perspectives

China's Drug Firms Surpass $100B, Innovation Set to Soar

12/28/2025

50 10

Summary

Story summary

In 2025, China's innovative drug firms surpassed $100 billion in licensing, signaling a shift to an innovation powerhouse.
Pfizer announced a $12.5 billion oncology deal, while GSK acquired Hengrui's PD-1 inhibitors for $12.5 billion.
Innovent announced an $11.4 billion collaboration with Takeda.
Looking ahead, geopolitical risks and IP protection remain challenges, even as ADC and RNA therapies offer growth opportunities.

1 of 1

Story summary

In 2025, China's innovative drug firms surpassed $100 billion in licensing, signaling a shift to an innovation powerhouse.
Pfizer announced a $12.5 billion oncology deal, while GSK acquired Hengrui's PD-1 inhibitors for $12.5 billion.
Innovent announced an $11.4 billion collaboration with Takeda.
Looking ahead, geopolitical risks and IP protection remain challenges, even as ADC and RNA therapies offer growth opportunities.